|Assessment Status||Rapid review complete|
|Indication||For adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance.|
|Rapid review commissioned||13/12/2021|
|Rapid review completed||08/02/2022|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that dupilumab (Dupixent®) not be considered for reimbursement at the submitted price*|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.